The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2014 | Prof Claire Harrison at ASH 2014 Highlights on myeloproliferative neoplasms
A molecular-based approach in MPN studies, which has improved understanding of driver mutations, has rapidly increased recent advances in clinical management. Combinational therapies are in preliminary stages and focus is on the Janus kinase (JAK) inhibitor, ruxolitinib, in combinations that enhance overall patient response. Long-term studies, such as the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study, are providing insight in high-risk patients with essential thrombocythemia (ET). Quality of life in MPN patients is also addressed.
